Cabaletta Bio (CABA) Interest & Investment Income (2018 - 2025)
Cabaletta Bio's quarterly Interest & Investment Income came in at $1.3 million in Q4 2025, down 31.9% year-on-year from $1.9 million in Q4 2024, and down 26.66% quarter-over-quarter from $1.8 million in Q3 2025.
Cabaletta Bio has reported Interest & Investment Income for 8 years, with the latest figure at $1.3 million in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income fell 31.9% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $6.0 million (down 39.84% YoY), and the FY2025 full-year result was $6.0 million, down 39.84% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $1.3 million, down from $1.8 million in the prior quarter.
- The five-year high for Interest & Investment Income was $3.0 million in Q1 2024, with the low at $3000.0 in Q3 2021.
- Average Interest & Investment Income over 5 years is $1.2 million, with a median of $1.4 million recorded in 2023.
- Year-over-year, Interest & Investment Income plunged 97.56% in 2021 and surged 12100.0% in 2022.
- Tracing CABA's Interest & Investment Income over 5 years: stood at $5000.0 in 2021, then surged by 12100.0% to $610000.0 in 2022, then soared by 270.49% to $2.3 million in 2023, then declined by 13.85% to $1.9 million in 2024, then sank by 31.9% to $1.3 million in 2025.
- The last three Interest & Investment Income figures came in at $1.3 million (Q4 2025), $1.8 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.68 Mn |
| Mar 31, 2024 | 2.98 Mn |
| Dec 31, 2023 | 2.26 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 610,000.00 |
| Sep 30, 2022 | 351,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 21,000.00 |
| Sep 30, 2020 | 23,000.00 |
| Jun 30, 2020 | 40,000.00 |
| Mar 31, 2020 | 410,000.00 |
| Dec 31, 2019 | 457,000.00 |
| Sep 30, 2019 | 381,000.00 |
| Jun 30, 2019 | 444,000.00 |
| Mar 31, 2019 | 458,000.00 |
| Dec 31, 2018 | 160,000.00 |
| Sep 30, 2018 | 48,000.00 |